Search

Your search keyword '"Sendra Rumbeu P"' showing total 8 results
Start Over Author "Sendra Rumbeu P"
8 results on '"Sendra Rumbeu P"'

1. DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study

Author

Chaparro, M, primary, Hermida, S, additional, Acosta, D, additional, Fernández-Clotet, A, additional, Barreiro-de Acosta, M, additional, Hernández Martínez, Á, additional, Arroyo, M, additional, Bosca-Watts, M M, additional, Diz-Lois Palomares, M T, additional, Menchén, L, additional, Martínez Cadilla, J, additional, Leo-Carnerero, E, additional, Muñoz Villafranca, C, additional, Sierra-Ausín, M, additional, González, Y, additional, Riestra, S, additional, Sendra Rumbeu, P, additional, Cabello Tapia, M J, additional, García de la Filia, I, additional, Montil Miguel, E, additional, Ceballos, D, additional, Pajares Villarroya, R, additional, Ramírez de la Piscina, P, additional, Martín-Arranz, M D, additional, Ramos, L, additional, Ruiz-Cerulla, A, additional, Teresa de Jesús, M P, additional, San Miguel, E, additional, Calvet, X, additional, Huguet, J M, additional, Keco-Huerga, A, additional, Lorente Poyatos, R H, additional, Muñoz, J F, additional, Ponferrada, Á, additional, Sicilia Aladrén, B, additional, Delgado-Guillena, P, additional, Gómez Delgado, E, additional, Rancel-Medina, F J, additional, Alonso-Galán, H, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

2. P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding

Author

Chaparro, M, primary, García Donday, M, additional, Rubio, S, additional, Calviño Suarez, C, additional, Nuñez Ortiz, A, additional, Figueira, M, additional, Marín Pedrosa, S, additional, Rivero, M, additional, Fernández-Clotet, A, additional, Madero, L, additional, Diz-Lois Palomares, M T, additional, Pérez-Martínez, I, additional, Ruiz-Cerulla, A, additional, Arroyo, M, additional, Piqueras, M, additional, Suarez Ferrer, C, additional, Aguas, M, additional, Calvo Moya, M, additional, Guerra, I, additional, López Serrano, P, additional, Vázquez Morón, J M, additional, Arias García, L, additional, Casanova, M J, additional, Huguet, J M, additional, Valldosera Gomis, G, additional, Zúñiga de Mora-Figueroa, B, additional, Armesto, R, additional, Martínez Montiel, P, additional, Rodríguez-Lago, I, additional, Sendra Rumbeu, P, additional, Camargo Camero, R, additional, Hervías Cruz, D, additional, Molina Arriero, G, additional, Barreiro-de Acosta, M, additional, Acosta, D, additional, Brenes, Y, additional, Hermida, S, additional, Parra, P, additional, Garre, A, additional, and Gisbert, J P, additional

Published
2023
Full Text
View/download PDF

3. P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

Author

Chaparro, M, primary, Donday, M G, additional, Rubio, S, additional, Nuñez, A, additional, Calviño Suarez, C, additional, Madero, L, additional, Figueira, M, additional, Rivero, M, additional, Pérez Martínez, I, additional, Diz-Lois Palomares, M T, additional, Huguet, J M, additional, Marín Pedrosa, S, additional, Aguas, M, additional, Arroyo, M, additional, Ruiz-Cerulla, A, additional, Vázquez Morón, J M, additional, Fernández-Clotet, A, additional, Guerra, I, additional, López Serrano, P, additional, Rodríguez-Lago, I, additional, Arias García, L, additional, Camargo Camero, R, additional, Casanova, M J, additional, Martínez Montiel, P, additional, Sendra Rumbeu, P, additional, Suarez Ferrer, C, additional, Valldosera Gomis, G, additional, Armesto, R, additional, Bujanda, L, additional, Calvo Moya, M, additional, Hervías Cruz, D, additional, Robles Alonso, V, additional, de Jorge Turrión, M Á, additional, Zúñiga de Mora-Figueroa, B, additional, Molina Arriero, G, additional, Acosta, D, additional, Brenes, Y, additional, Hermida, S, additional, Parra, P, additional, and Gisbert, J P, additional

Published
2022
Full Text
View/download PDF

4. DOP52 Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)

Author

Chaparro, M, primary, García Donday, M, additional, Calviño Suarez, C, additional, Rubio, S, additional, Figueira, M, additional, Pérez Martínez, I, additional, Leo Carnerero, E, additional, Rodríguez Lago, I, additional, Ruiz Cerulla, A, additional, Aguas, M, additional, López Serrano, P, additional, Ramírez de la Piscina Urraca, P, additional, Rivero, M, additional, Suarez Ferrer, C, additional, Alfambra Cabrejas, E, additional, Armesto, R, additional, Diz-Lois Palomares, M T, additional, Guerra, I, additional, Vázquez Morón, J M, additional, Casanova, M J, additional, Hervías Cruz, D, additional, Huguet, J M, additional, de Jorge Turrión, M Á, additional, Marín Pedrosa, S, additional, Molina Arriero, G, additional, Ramos, L, additional, Zúñiga de Mora-Figueroa, B, additional, Camargo Camero, R, additional, Fernández-Clotet, A, additional, Gutiérrez Casbas, A, additional, Martínez Montiel, P, additional, Rodríguez Insa, R, additional, Sendra Rumbeu, P, additional, Tardillo Marín, C, additional, Vicente Lidón, R, additional, Arias García, L, additional, Bujanda, L, additional, Lucendo, A J, additional, Manceñido Marcos, N, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

7. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

Author

Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, Arroyo M, Bosca-Watts MM, Diz-Lois Palomares MT, Menchén L, Martínez Cadilla J, Leo-Carnerero E, Muñoz Villafranca C, Sierra-Ausín M, González-Lama Y, Riestra S, Sendra Rumbeu P, Cabello Tapia MJ, García de la Filia I, Vicente R, Ceballos D, Pajares Villarroya R, Ramírez de la Piscina P, Martín-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Pérez TJ, San Miguel Amelivia E, Calvet X, Huguet JM, Keco-Huerga A, Lorente Poyatos RH, Muñoz JF, Ponferrada-Díaz Á, Sicilia B, Delgado-Guillena P, Gómez Delgado E, Rancel-Medina FJ, Alonso-Galán H, Herreros B, Rivero M, Varela P, Bermejo F, García Sepulcre M, Gimeno-Pitarch L, Kolle-Casso L, Márquez-Mosquera L, Martínez Tirado P, Ramírez C, Sesé Abizanda E, Dueñas Sadornil C, Fernández Rosáenz H, Gutiérrez Casbas A, Madrigal Domínguez RE, Nantes Castillejo Ó, Ber Nieto Y, Botella Mateu B, Frago Larramona S, López Serrano P, Rubio Mateos JM, Torrá Alsina S, Iyo E, Fernández Forcelledo JL, Hernández L, Rodríguez-Grau MC, Monfort Miquel D, Van Domselaar M, López Ramos C, Ruiz Barcia MJ, and Gisbert JP

Subjects
Humans, Male, Female, Retrospective Studies, Adult, Middle Aged, Treatment Outcome, Remission Induction, Severity of Illness Index, Ustekinumab therapeutic use, Colitis, Ulcerative drug therapy
Abstract

Background: Ustekinumab is approved for ulcerative colitis (UC)., Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice., Methods: Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission., Results: We included 620 patients; 155 (25%) discontinued ustekinumab during follow-up (median 12 months). Rate of discontinuation was 20% per patient-year of follow-up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1-2.1), steroids at baseline (HR 1.5; 95% CI 1.06-2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09-2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid-free clinical remission. Moderate-severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2-0.5), male sex (OR 0.5; 95% CI 0.4-0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6-0.8) were associated with lower likelihood of steroid-free clinical remission at week 16. One hundred and seventy-six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune-mediated diseases., Conclusions: Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies., (© 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

8. Endoscopic management of duodenal levodopa-carbidopa therapy of advanced Parkinson's disease.

Author

Garrido Durán C, Khorrami Minaei S, Sendra Rumbeu P, Fernández García J, García Hernández M, and Legarda Ramírez I

Subjects
Aged, Drug Combinations, Female, Humans, Male, Middle Aged, Retrospective Studies, Antiparkinson Agents administration & dosage, Carbidopa administration & dosage, Duodenoscopy adverse effects, Gastrostomy adverse effects, Levodopa administration & dosage, Parkinson Disease drug therapy
Abstract

Background: treatment of intraduodenal levodopa using percutaneous endoscopic gastrostomy is an alternative therapy in patients with advanced Parkinson's disease. There are few studies that have evaluated the endoscopic aspects of this technique., Objectives: to describe our experience and adverse events regarding this technique in advanced Parkinson's disease., Method: a retrospective study was performed from January 2007 to January 2019 in a tertiary healthcare center., Results: thirty-seven patients aged 65.1 ± 10.3 years were included in the study, 21 were male and the disease duration was ten years (1-26). The median follow-up was 16 months (1-144). The device was successfully placed in all cases. The persistence rate with the PEG-D at the end of follow-up was 62.2%. The system was removed in 14 patients, seven due to neurological impairment, four because of the decision of the patient and three due to related events. Fifty-nine adverse events occurred in 23 patients (62.2%, 0.63 per patient-year), four of which were severe (8.1%, 0.05 per patient-year). Minor adverse events included 14 (37.8%) related to the stoma, six (16.2%) to the gastric tube and 15 (40.5%) to the duodenal tube. Forty-four system replacements were performed in 20 patients (54.1%, 0.52 per patient-year). Male sex, age over 70 and a higher comorbidity index were associated with a greater likelihood of persistence of the system (OR: 0.14, 95% CI: 0.03-0.62; OR: 0.52, 95% CI: 0.32-0.86; OR: 0.16, 95% CI: 0.03-0.99, respectively). No predictors of adverse events associated with PEG-D were identified., Conclusions: percutaneous endoscopic gastrostomy for the continuous delivery of duodenal levodopa is a highly effective technique. Adverse events are common, although most are resolved by endoscopy.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results